These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 7871742

  • 1. Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation.
    Mahalingam S, Khan SA, Jabbar MA, Monken CE, Collman RG, Srinivasan A.
    Virology; 1995 Feb 20; 207(1):297-302. PubMed ID: 7871742
    [Abstract] [Full Text] [Related]

  • 2. Role of the conserved dipeptide Gly75 and Cys76 on HIV-1 Vpr function.
    Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A.
    Virology; 1995 Jul 10; 210(2):495-500. PubMed ID: 7618286
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag.
    Checroune F, Yao XJ, Göttlinger HG, Bergeron D, Cohen EA.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep 01; 10(1):1-7. PubMed ID: 7648278
    [Abstract] [Full Text] [Related]

  • 5. The carboxy-terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles.
    Mahalingam S, Patel M, Collman RG, Srinivasan A.
    Virology; 1995 Dec 20; 214(2):647-52. PubMed ID: 8553570
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.
    Mahalingam S, Khan SA, Murali R, Jabbar MA, Monken CE, Collman RG, Srinivasan A.
    Proc Natl Acad Sci U S A; 1995 Apr 25; 92(9):3794-8. PubMed ID: 7731985
    [Abstract] [Full Text] [Related]

  • 8. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.
    Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA.
    J Virol; 1995 Nov 25; 69(11):7032-44. PubMed ID: 7474123
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mutational analysis of the conserved cysteine residues in the simian immunodeficiency virus matrix protein.
    González SA, Affranchino JL.
    Virology; 1995 Jul 10; 210(2):501-7. PubMed ID: 7618287
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro.
    Li MS, Garcia-Asua G, Bhattacharyya U, Mascagni P, Austen BM, Roberts MM.
    Biochem Biophys Res Commun; 1996 Jan 05; 218(1):352-5. PubMed ID: 8573160
    [Abstract] [Full Text] [Related]

  • 13. A carboxy-terminally truncated form of the Vpr protein of human immunodeficiency virus type 1 retards cell proliferation independently of G(2) arrest of the cell cycle.
    Nishizawa M, Myojin T, Nishino Y, Nakai Y, Kamata M, Aida Y.
    Virology; 1999 Oct 25; 263(2):313-22. PubMed ID: 10544105
    [Abstract] [Full Text] [Related]

  • 14. A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions.
    Kulkosky J, BouHamdan M, Geist A, Pomerantz RJ.
    Virology; 1999 Mar 01; 255(1):77-85. PubMed ID: 10049823
    [Abstract] [Full Text] [Related]

  • 15. NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions.
    Schüler W, Wecker K, de Rocquigny H, Baudat Y, Sire J, Roques BP.
    J Mol Biol; 1999 Feb 05; 285(5):2105-17. PubMed ID: 9925788
    [Abstract] [Full Text] [Related]

  • 16. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.
    Kondo E, Mammano F, Cohen EA, Göttlinger HG.
    J Virol; 1995 May 05; 69(5):2759-64. PubMed ID: 7707498
    [Abstract] [Full Text] [Related]

  • 17. Residues within the HFRIGC sequence of HIV-1 vpr involved in growth arrest activities.
    Berglez JM, Castelli LA, Sankovich SA, Smith SC, Curtain CC, Macreadie IG.
    Biochem Biophys Res Commun; 1999 Oct 14; 264(1):287-90. PubMed ID: 10527879
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M, Kulkosky J, Duan LX, Pomerantz RJ.
    J Hum Virol; 2000 Oct 14; 3(1):6-15. PubMed ID: 10774802
    [Abstract] [Full Text] [Related]

  • 19. Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest.
    Zhou Y, Lu Y, Ratner L.
    Virology; 1998 Mar 15; 242(2):414-24. PubMed ID: 9514978
    [Abstract] [Full Text] [Related]

  • 20. Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo.
    Votteler J, Studtrucker N, Sörgel S, Münch J, Rücker E, Kirchhoff F, Schick B, Henklein P, Fossen T, Bruns K, Sharma A, Wray V, Schubert U.
    J Virol; 2007 Sep 15; 81(17):9572-6. PubMed ID: 17553868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.